Literature DB >> 28687538

Temporal Trends of Single-Photon Emission Computed Tomography Myocardial Perfusion Imaging in Patients With Coronary Artery Disease: A 22-Year Experience From a Tertiary Academic Medical Center.

Hayan Jouni1, J Wells Askew1, Daniel J Crusan1, Todd D Miller1, Raymond J Gibbons2.   

Abstract

BACKGROUND: There has been a gradual decline in the prevalence of abnormal stress single-photon emission computed tomography (SPECT) myocardial perfusion imaging studies among patients without history of coronary artery disease (CAD). The trends of SPECT studies among patients with known CAD have not been evaluated previously. METHODS AND
RESULTS: We assessed the Mayo Clinic nuclear cardiology database for all stress SPECT tests performed between January 1991 and December 2012 in patients with history of CAD defined as having previous myocardial infarction, percutaneous coronary intervention, and coronary artery bypass grafting. The study cohort was divided into 5 time periods: 1991 to 1995, 1996 to 2000, 2001 to 2005, 2006 to 2010, and 2011 to 2012. There were 19 373 patients with a history of CAD who underwent SPECT between 1991 and 2012 (mean age, 66.2±10.9 years; 75.4% men). Annual utilization of SPECT in these patients increased from an average of 495 tests per year in 1991 to 1995 to 1425 in 2003 and then decreased to 552 tests in 2012 without evidence for substitution with other stress modalities. Asymptomatic patients initially increased until 2006 and then decreased. Patients with typical angina decreased, whereas patients with dyspnea and atypical angina increased. High-risk SPECT tests significantly decreased, and the percentage of low-risk SPECT tests increased despite decreased SPECT utilization between 2003 and 2012. Almost 80% of all tests performed in 2012 had a low-risk summed stress score compared with 29% in 1991 (P<0.001).
CONCLUSIONS: In Mayo Clinic, Rochester, annual SPECT utilization in patients with previous CAD increased between 1992 and 2003, but then decreased after 2003. High-risk SPECT tests declined, whereas low-risk tests increased markedly. Our results suggest that among patients with a history of CAD, SPECT was being increasingly utilized in patients with milder CAD. This trend parallels reduced utilization of other stress modalities, coronary angiography, reduced smoking, and greater utilization of optimal medical therapy for prevention and treatment of CAD.
© 2017 American Heart Association, Inc.

Entities:  

Keywords:  coronary artery bypass; coronary artery disease; myocardial infarction; tomography, emission-computed, single-photon; trends

Mesh:

Year:  2017        PMID: 28687538     DOI: 10.1161/CIRCIMAGING.116.005628

Source DB:  PubMed          Journal:  Circ Cardiovasc Imaging        ISSN: 1941-9651            Impact factor:   7.792


  10 in total

1.  LVEF reserve: State of the heart is a matter of time, jeopardy and ischemic memory.

Authors:  Michael V Hannon; Ronald G Schwartz
Journal:  J Nucl Cardiol       Date:  2021-01-01       Impact factor: 5.952

2.  Temporal trends in test utilization and prevalence of ischaemia with positron emission tomography myocardial perfusion imaging.

Authors:  Firas J Al Badarin; Paul S Chan; John A Spertus; Randall C Thompson; Krishna K Patel; Kevin F Kennedy; Timothy M Bateman
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2020-03-01       Impact factor: 6.875

3.  Randomized Comparison of Clinical Effectiveness of Pharmacologic SPECT and PET MPI in Symptomatic CAD Patients.

Authors:  Krishna K Patel; Firas Al Badarin; Paul S Chan; John A Spertus; Staci Courter; Kevin F Kennedy; James A Case; A Iain McGhie; Gary V Heller; Timothy M Bateman
Journal:  JACC Cardiovasc Imaging       Date:  2019-07-17

Review 4.  Role of nuclear cardiology in diagnosis and risk stratification of coronary microvascular disease.

Authors:  Terrence D Ruddy; Anahita Tavoosi; Viviany R Taqueti
Journal:  J Nucl Cardiol       Date:  2022-07-18       Impact factor: 3.872

Review 5.  The Synergistic Use of Coronary Artery Calcium Imaging and Noninvasive Myocardial Perfusion Imaging for Detecting Subclinical Atherosclerosis and Myocardial Ischemia.

Authors:  Alan Rozanski; Daniel S Berman
Journal:  Curr Cardiol Rep       Date:  2018-06-13       Impact factor: 2.931

6.  MPI in the era of CZT cameras: Absolute numbers are still better than relative figures.

Authors:  Riccardo Liga; Alessia Gimelli
Journal:  J Nucl Cardiol       Date:  2019-06-07       Impact factor: 5.952

7.  Temporal trends of abnormal myocardial perfusion imaging in a cohort of Italian subjects: Relation with cardiovascular risk factors.

Authors:  Rosario Megna; Emilia Zampella; Roberta Assante; Carmela Nappi; Valeria Gaudieri; Teresa Mannarino; Valeria Cantoni; Roberta Green; Stefania Daniele; Ciro Gabriele Mainolfi; Wanda Acampa; Mario Petretta; Alberto Cuocolo
Journal:  J Nucl Cardiol       Date:  2019-02-07       Impact factor: 5.952

8.  Pretest models for predicting abnormal stress single-photon emission computed tomography myocardial perfusion imaging.

Authors:  Rosario Megna; Roberta Assante; Emilia Zampella; Valeria Gaudieri; Carmela Nappi; Renato Cuocolo; Teresa Mannarino; Andrea Genova; Roberta Green; Valeria Cantoni; Wanda Acampa; Mario Petretta; Alberto Cuocolo
Journal:  J Nucl Cardiol       Date:  2019-11-11       Impact factor: 5.952

9.  High-frequency QRS analysis to supplement ST evaluation in exercise stress electrocardiography: Incremental diagnostic accuracy and net reclassification.

Authors:  Pelbreton C Balfour; Jorge A Gonzalez; Peter W Shaw; Margarita P Caminero; Eric M Holland; Jack W Melson; Michael Sobczak; Valerie Izarnotegui; Denny D Watson; George A Beller; Jamieson M Bourque
Journal:  J Nucl Cardiol       Date:  2018-11-30       Impact factor: 5.952

10.  Coronary Disease Surveillance in the Community: Angiography and Revascularization.

Authors:  Yariv Gerber; Raymond J Gibbons; Susan A Weston; Matteo Fabbri; Joerg Herrmann; Sheila M Manemann; Robert L Frye; Rabea Asleh; Kevin Greason; Jill M Killian; Véronique L Roger
Journal:  J Am Heart Assoc       Date:  2020-04-02       Impact factor: 5.501

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.